MedTrace Logo

Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function

NCT00189085 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-06-10

No results posted yet for this study

Summary

In the present study the investigators are researching the effects of the cholesterol absorption inhibitor ezetimibe on postprandial lipemia and postprandial endothelial function in patients with the metabolic syndrome. The lipid-lowering effect of high-dose statin monotherapy on fasting lipids is equal to the combination therapy of low-dose statin and ezetimibe.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

simvastatin and ezetimibe

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Frank LJ Visseren, MD PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189085 on ClinicalTrials.gov